Bimiralisib

CAS : 1225037-39-7

Ref. TM-T2265

Informations sur le produit

• Nom: Bimiralisib
• Synonymes: 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine, PQR309, PI3K-IN-2
• CAS: 1225037-39-7

Description

Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.

• Marque: Targetmol

Propriétés chimiques

• Masse moléculaire: 411.38
• Formule: C₁₇H₂₀F₃N₇O₂
• Degré de pureté: 99.88%
• Couleur/Forme: Solid
• InChI: InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)
• Code InChI: InChIKey=ADGGYDAFIHSYFI-UHFFFAOYSA-N
• SMILES: Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1